ClinicalTrials.gg
RecruitingNCT07366034Updated Nov 10, 2026

A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)

A Phase 3 interventional study of Nerandomilast and Placebo in Fibrosing Interstitial Lung Disease, sponsored by Boehringer Ingelheim. Recruiting at 47 sites in 22 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Updated Nov 10, 2026Site recruiting status changed2 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Lung Diseases, Interstitial by Boehringer Ingelheim — 4 open to participants now, 6 under way, 4 of them phase 3. Lung Diseases, Interstitial · Boehringer Ingelheim.

Planned enrollment
11th of 12
35 · median 248
Started
2026
with 2 others
Phase 3
11 of 24
3 open now
Registered
23rd of 24
by date

Among the 24 studies in Lung Diseases, Interstitial by Boehringer Ingelheim, this one is the 11th largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2026, is one of 11 in phase 3, and was the 23rd registered.

Lung Diseases, Interstitial

682 studies on the registry are indexed under Lung Diseases, Interstitial; 246 are open to participants now.

Browse Lung Diseases, Interstitial studies →

Open to participants now

4 of the 24 studies in Lung Diseases, Interstitial by Boehringer Ingelheim are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 173 Lung Diseases, Interstitial studies recruiting now, 108 (62%) set no upper age limit and 25 (14%) stop at 75 or younger; 13 take children under 18; 21 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Lung Diseases, Interstitial by Boehringer Ingelheim, or all of them as a file.
02

Study summary

This study is open to children and adolescents aged 2 to 17 years with interstitial lung disease (ILD). Nerandomilast has just been approved in some countries to help adults with a lung condition called idiopathic pulmonary fibrosis. The purpose of this study is to understand how nerandomilast is tolerated and handled by the body and whether nerandomilast also helps children and adolescents with ILD.

For participants aged 6 to 17 years when joining, the study has 2 parts. In the first part, participants are put into 1 of 2 groups randomly, which means by chance. One group gets nerandomilast and the other group placebo. Placebo looks like nerandomilast but does not contain any medicine.

Participants are twice as likely to be in the nerandomilast group. They take tablets twice a day for 6 months. After these 6 months, in the second part of this study, they get nerandomilast for at least 2 years regardless of what they got in the first part.

Young participants aged 2 to 5 years when joining get nerandomilast from the start. They receive tablets twice a day for at least 2 and a half years.

Depending on when a person joins, the study lasts between 2 and a half years and up to 5 years. During this time, participants may visit the study site about 18 to 30 times. Study doctors collect blood samples to check participants' health and to find out how their body handles the study medicine. Doctors also check the function of the lungs, body growth, and how participants feel. The study doctors also regularly check participants' health and take note of any changes. For participants aged 6 to 17 years, the results are compared between the groups to see whether nerandomilast treatment helps children and adolescents.

03

Conditions studied

  • Fibrosing Interstitial Lung Disease
04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children and adolescents 2 to \<18 years old at Visit 2.
  • Participants with evidence of fibrosing ILD on high-resolution computed tomography (HRCT) within 12 months of Visit 1 as assessed by the investigator and confirmed by central review.
  • For children ≥6 years: Participants with forced vital capacity (FVC) % predicted ≥25% at Visit 2.
  • Participants with fibrosing ILD at Visit 2, as assessed by the investigator based on any of the following:

    • Fan score ≥3, or
    • Documented evidence of clinical progression over time based on either

      • a 5-10% relative decline in FVC % predicted accompanied by worsening symptoms, or
      • a ≥10% relative decline in FVC % predicted, or
      • increased fibrosis on HRCT, or
      • other measures of clinical worsening attributed to progressive lung disease (e.g. increased oxygen requirement, decreased diffusion capacity).

Further inclusion criteria apply.

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with nerandomilast.
  • Participants treated with other oral/systemic PDE4 and non-selective PDE inhibitors within 30 days before Visit 1.
  • Participants treated with pirfenidone in the 8 weeks prior to Visit 1.
  • Unstable pulmonary arterial hypertension (PAH).
  • Active vasculitis, unstable or uncontrolled within 8 weeks prior to Visit 1 or during the screening period.
  • Any suicidal behaviour (i.e. actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behaviour) in the past (lifetime).
  • Any suicidal ideation of type 4 or 5 on the columbia suicidal severity rating scale (C-SSRS) in the past 3 months at Visit 1 or at Visit 2 (i.e. active suicidal thought with method and intent but without specific plan; or active suicidal thought with method, intent, and plan).
  • Participants with depression symptoms defined as the short version of mood and feeling questionnaire (SMFQ) score ≥8.

Further exclusion criteria apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    Participants aged 2 to <6 years

    Part A and Part B: Nerandomilast (open-label)

    Drug: Nerandomilast

  • Experimental
    Participants aged 6 to <18 years, group 1

    Part A: Nerandomilast (blinded), Part B: Nerandomilast (open-label)

    Drug: Nerandomilast

  • Experimental
    Participants aged 6 to <18 years, group 2

    Part A: Placebo (blinded), Part B: Nerandomilast (open-label)

    Drug: Placebo

Interventions

  • Nerandomilast

    Also known as: JASCAYD®

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Area under the concentration curve (AUC) T,SS based on sampling at steady state using rich sampling in participants from 6 years to less than 18 years and sparse sampling in participants younger than 6 years

    Time frame: At week 2 in Part A and Week 28 in Part B

  2. Occurrence of a treatment-emergent adverse event

    Time frame: up to Week 26

Secondary outcomes

  1. Absolute change from baseline in oxygen saturation (SpO2) [%] on room air at rest

    Time frame: at Week 26 and Week 52

  2. Absolute change from baseline in height [cm]

    Time frame: at Week 26 and Week 52

  3. Absolute change from baseline in pediatric quality of life inventory (PedsQL™)

    Health-related quality of life will be assessed in children using the PedsQL™ questionnaire. For younger children who are unable to perform self-assessment, a parent proxy may be required. The score ranges from 0-100, a higher score indicates a better health related quality of life.

    Time frame: at Week 26 and Week 52

  4. Occurrence of a treatment-emergent adverse event (Yes/No) over the whole trial

    Time frame: up to 5 years

  5. Time to first respiratory-related hospitalisation [days] over the whole trial

    Time frame: up to 5 years

  6. Time to first acute interstitial lung disease (ILD) exacerbation or death [days] over the whole trial

    Time frame: up to 5 years

  7. Time to death [days] over the whole trial

    Time frame: up to 5 years

  8. Acceptability based on number/size of tablets

    Acceptability is defined as the overall ability and willingness of the participant to use the medicinal product as intended. Assessment of acceptability will be performed by the participant using the acceptability questionnaire.

    Time frame: at Week 2 and Week 26

  9. Acceptability based on the use of the dispenser

    Time frame: at Week 2 and Week 26

  10. Absolute change from baseline in FVC [% predicted] (applicable to participants ≥6 years)

    Time frame: at Week 26 and Week 52

  11. Absolute change from baseline in 6-min walk distance [m] (applicable to participants ≥6 years)

    Time frame: at Week 26 and Week 52

07

Study locations

26 of 47 sites recruiting
08

References and documents

Related links

Individual participant data

Plan to share: Yes — Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.

Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.clinicalstudies.boehringer-ingelheim.com

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Apr 2029, 33 months after the start.

Of 36 phase 3 interventional studies under Lung Diseases, Interstitial, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 61. This study's planned 33 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2026
First posted
Jan 26, 2026
StartActual
Jul 21, 2026
Primary completionEst.
Apr 27, 2029
CompletionEst.
Apr 14, 2031
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 2 sites removed. 14 sites changed recruiting status (14 now recruiting)
Show 14 sites
  • Associação dos Funcionários Públicos do Estado do Rio Grande do Sul - Hospital Ernesto Dorneles · Porto Alegre, BrazilNot yet recruiting→Recruiting
  • IMIP Pernambuco · Recife, BrazilNot yet recruiting→Recruiting
  • Charité - Universitätsmedizin Berlin · Berlin, GermanyNot yet recruiting→Recruiting
  • Hospital Virgen del Rocio · Seville, SpainNot yet recruiting→Recruiting
  • Boston Children's Hospital · Boston, United StatesNot yet recruiting→Recruiting
  • Women's and Children's Hospital · North Adelaide, AustraliaNot yet recruiting→Recruiting
  • Brussels - UNIV HUDERF · Brussels, BelgiumNot yet recruiting→Recruiting
  • HOP Femme Mère Enfant · Bron, FranceNot yet recruiting→Recruiting
  • National Center for Child Health and Development · Tokyo, Setagaya-ku, JapanNot yet recruiting→Recruiting
  • Children's Hospital Colorado · Aurora, United StatesNot yet recruiting→Recruiting
  • M Health Fairview Masonic Children's Hospital · Minneapolis, United StatesNot yet recruiting→Recruiting
  • HOP Intercommunal · Créteil, FranceNot yet recruiting→Recruiting
  • Hamburger Zentrum für Kinder- und Jugendrheumatologie · Hamburg, GermanyNot yet recruiting→Recruiting
  • King's College Hospital · London, United KingdomNot yet recruiting→Recruiting
Show 2 added (1 Portugal, 1 Spain)
  • ULS de Santa Maria, E.P.E - Hospital de Santa Maria · Lisbon, Portugal
  • Hospital Universitario Virgen del Rocio · Seville, Spain
Show 2 removed
  • ULS de Santa Maria, E.P.E · Lisbon, Portugal
  • Hospital Virgen del Rocio · Seville, Spain
across 4 updates, Sep 29, 2026 – Nov 10, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • HUS Lasten ja nuorten sairaudet, Kliinisen tutkimuksen yksikkö · Helsinki, FinlandContact removed s•••@bitrialsupport.com · •••8118
Sep 29, 2026
Show all 4 updates
  1. Nov 10, 2026
    2 sites added, 2 sites removed. 2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Hamburger Zentrum für Kinder- und Jugendrheumatologie · Hamburg, GermanyNot yet recruiting→Recruiting
    • King's College Hospital · London, United KingdomNot yet recruiting→Recruiting
    Show 2 added (1 Portugal, 1 Spain)
    • ULS de Santa Maria, E.P.E - Hospital de Santa Maria · Lisbon, Portugal
    • Hospital Universitario Virgen del Rocio · Seville, Spain
    Show 2 removed
    • ULS de Santa Maria, E.P.E · Lisbon, Portugal
    • Hospital Virgen del Rocio · Seville, Spain
    + 1 other change: verification date
  2. Oct 27, 2026
    3 sites changed recruiting status (3 now recruiting)
    Show 3 sites
    • Children's Hospital Colorado · Aurora, United StatesNot yet recruiting→Recruiting
    • M Health Fairview Masonic Children's Hospital · Minneapolis, United StatesNot yet recruiting→Recruiting
    • HOP Intercommunal · Créteil, FranceNot yet recruiting→Recruiting
  3. Oct 13, 2026
    5 sites changed recruiting status (5 now recruiting)
    Show 5 sites
    • Boston Children's Hospital · Boston, United StatesNot yet recruiting→Recruiting
    • Women's and Children's Hospital · North Adelaide, AustraliaNot yet recruiting→Recruiting
    • Brussels - UNIV HUDERF · Brussels, BelgiumNot yet recruiting→Recruiting
    • HOP Femme Mère Enfant · Bron, FranceNot yet recruiting→Recruiting
    • National Center for Child Health and Development · Tokyo, Setagaya-ku, JapanNot yet recruiting→Recruiting
    + 1 other change: verification date
  4. Sep 29, 2026
    4 sites changed recruiting status (4 now recruiting)
    Show 4 sites
    • Associação dos Funcionários Públicos do Estado do Rio Grande do Sul - Hospital Ernesto Dorneles · Porto Alegre, BrazilNot yet recruiting→Recruiting
    • IMIP Pernambuco · Recife, BrazilNot yet recruiting→Recruiting
    • Charité - Universitätsmedizin Berlin · Berlin, GermanyNot yet recruiting→Recruiting
    • Hospital Virgen del Rocio · Seville, SpainNot yet recruiting→Recruiting
    Site contacts Changed at 1 site. See the sites
    Show the site
    • HUS Lasten ja nuorten sairaudet, Kliinisen tutkimuksen yksikkö · Helsinki, FinlandContact removed s•••@bitrialsupport.com · •••8118

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07366034
Responsible party
Sponsor
First posted
Jan 26, 2026
Start date
Jul 21, 2026
Primary completion
Apr 27, 2029 (estimated)
Completion
Apr 14, 2031 (estimated)
Last update
Nov 10, 2026

Study contacts

Boehringer Ingelheim
Contact
clintriage.rdg@boehringer-ingelheim.com
1-800-243-0127

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nerandomilast

Start the discussion